Cogent Biosciences, Inc. (COGT) Q3 2025 10-Q Quarterly Report
Cogent Biosciences, Inc. (COGT) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Nov 7, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.
Cogent Biosciences, Inc. Q3 2025 10-Q Analysis
Risk Factors
- • New financing risk due to $400M Credit Facility with SLR, $75M tranche contingent on positive Phase 3 PEAK data
- • Updated covenant risk includes restrictive terms limiting operations, acquisitions, and licensing under Loan and Security Agreement
Cogent Biosciences, Inc. Q3 2025 Quarterly FinancialsXBRL
Net Income
-$81M
▼ -14.6% YoY▼ -10.1% QoQ
ROE
-26.8%
Total Assets
$426M
EPS (Diluted)
$-0.50
▲ +21.9% YoY▲ +5.7% QoQ
Operating Cash Flow
-$64M
▼ -23.7% YoY▼ -17.9% QoQ
Source: XBRL data from Cogent Biosciences, Inc. Q3 2025 10-Q filing on SEC EDGAR. All figures in USD.
Get deeper insights on Cogent Biosciences, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.